



Urocortin 2 Gene Transfer Improves Heart Function in
Aged Mice
Citation for published version (APA):
Giamouridis, D., Gao, M. H., Lai, N. C., Guo, T., Miyanohara, A., Blankesteijn, W. M., Biessen, E. A. L., &
Hammond, H. K. (2020). Urocortin 2 Gene Transfer Improves Heart Function in Aged Mice. Molecular
Therapy, 28(1), 180-188. https://doi.org/10.1016/j.ymthe.2019.10.003





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Nov. 2021
Original ArticleUrocortin 2 Gene Transfer Improves
Heart Function in Aged Mice
Dimosthenis Giamouridis,1,2,3,4 Mei Hua Gao,1,2 N. Chin Lai,1,2 Tracy Guo,1,2 Atsushi Miyanohara,2
W. Matthijs Blankesteijn,3 Erik A.L. Biessen,4,5 and H. Kirk Hammond1,2
1Department of Medicine, University of California, San Diego, Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA; 2Department of Medicine,
University of California San Diego, San Diego, CA, USA; 3Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht
University, the Netherlands; 4Department of Pathology, Cardiovascular Research Institute, Maastricht University, the Netherlands; 5Institute for Molecular
Cardiovascular Research, RWTH Aachen University, Aachen, GermanyReceived 11 July 2019; accepted 4 October 2019;
https://doi.org/10.1016/j.ymthe.2019.10.003.
Correspondence: H. Kirk Hammond, Department of Medicine, University of
California, San Diego, Veterans Affairs San Diego Healthcare System, 3350 La Jolla
Village Drive, San Diego, CA 92161, USA.
E-mail: khammond@ucsd.eduPrevalence of left ventricular (LV) systolic and diastolic
dysfunction increases with aging. We previously reported
that urocortin 2 (Ucn2) gene transfer increases heart function
in mice with heart failure with reduced ejection fraction.
Here, we test the hypotheses that (1) Ucn2 gene transfer will
increase LV function in agedmice and that (2)Ucn2 gene trans-
fer given in early life will prevent age-related LV dysfunction.
Nineteen-month-old (treatment study) and 3-month-old (pre-
vention study) mice received Ucn2 gene transfer or saline. LV
function was examined 3–4 months (treatment study) or
20months (prevention study) afterUcn2 gene transfer or saline
injection. In both the treatment and prevention strategies,
Ucn2 gene transfer increased ejection fraction, reduced LV
volume, increased LV peak dP/dt and peak +dP/dt, and
reduced global longitudinal strain. Ucn2 gene transfer—in
both treatment and prevention strategies—was associated
with higher levels of LV SERCA2a protein, reduced phosphor-
ylation of LVCaMKIIa, and reduced LVa-skeletal actinmRNA
expression (reflecting reduced cardiac stress). In conclusion,
Ucn2 gene transfer restores normal cardiac function in mice
with age-related LV dysfunction and prevents development of
LV dysfunction.
INTRODUCTION
Heart failure (HF), a major cause of death, affects 6 million people
in the United States, and its prevalence increases with age.1 In
recent decades, it has become apparent that patients with preserved
left ventricular (LV) ejection fraction (EF) who have symptoms of
HF (HFpEF), formerly referred to as diastolic HF, should be
considered separately from those with HF and reduced EF
(HFrEF).2 Patients with HFpEF constitute up to 50% of the HF
population.3 They have abnormal ventricular filling, often due to
hypertension and to associated hypertrophy and increased stiffness
of the myocardium. HFpEF is associated with diabetes, myocardial
ischemia, and advanced age.3,4 In addition, there is usually
concomitant impaired systolic function when assessment is done
via less load-dependent indices of systolic function than EF, such
as peak rate of LV pressure development (+dP/dt) and global lon-
gitudinal strain (LV strain, hereinafter).5180 Molecular Therapy Vol. 28 No 1 January 2020There are several interventions (pharmacological and devices) that
reduce hospitalization rates and mortality in patients with HFrEF,
although the outlook remains poor even with optimal therapy. Unfor-
tunately, patients with HFpEF do not respond similarly to such inter-
ventions—pharmacological therapies can provide some symptom re-
lief, but do not influence clinical outcomes such as hospitalizations for
HF or mortality.4 Effective therapies for HFpEF are needed. In the
present study, we test the effectiveness of urocortin 2 (Ucn2) gene
transfer in mice as a treatment for and prevention of age-related
LV dysfunction, which includes both diastolic and systolic dysfunc-
tion in the setting of EF > 50%.
Ucn2, a member of the corticotropin-releasing factor (CRF) family, is
a 38-aa peptide that binds with high affinity to the corticotropin-
releasing hormone receptor 2 (CRHR2). A preclinical study found
that Ucn2 peptide infusion increased LV contractile function in
mice with HFrEF and improved LV diastolic function.6 Studies in
large animals7 and humans8–10 have confirmed the safety and
the beneficial effects of Ucn2 peptide infusion on measures of
heart function in HFrEF. To our knowledge, no clinical studies
have investigated the effects of Ucn2 peptide infusions in the setting
of HFpEF.
Considering the short half-life of Ucn2 (15 min),11 continuous
intravenous infusion of Ucn2 peptide would be necessary in order
to have sustained effects on the failing heart. This limitation pre-
cludes the use of Ucn2 peptide infusion as a long-term HF treat-
ment. To overcome this impediment, we have used Ucn2 gene
transfer to provide a sustained increase in the plasma levels of
Ucn2. We have previously demonstrated in preclinical studies
that such an approach is feasible. For example, intravenous
delivery of an adeno-associated virus vector encoding Ucn2
(AAV8.mUcn2) raised plasma Ucn2 levels and increased LV
Figure 1. Urocortin 2 Vector Construct and Plasma
Levels
(A) AAV8.CBA.mUcn2 vector map. ITR, inverted terminal
repeat; CMV.en, cytomegalovirus enhancer; CBA,
chicken b-actin promoter; Ucn2, murine urocortin 2;
bGpA, b-globin polyadenylation signal. (B) Study design.
(i) Aged mice study; (ii) prevention study. m.o., months
old; y.o., years old. (C) Ucn2 plasma levels in 3-month-
old (Young) and 2-year-old (Treatment) mice 4 months
after intravenous delivery of AAV8.mUcn2 (Ucn2, 1.9 
1013 gc/kg) or saline (Sal). Ucn2 plasma levels in 3-
month-old mice were studied 20 months (Prevention)
after saline (Sal) or AAV8.mUcn2 (Ucn2; 1.9  1013 gc/
kg) administration. Individual data are indicated (mean ±
SE). The p value is from Student’s t test (unpaired, two-
tailed); ***p < 0.001.
www.moleculartherapy.orgsystolic and diastolic function in normal mice and in mice with
HFrEF.12–14 However, Ucn2 gene transfer has not previously
been tested in mice with impaired diastolic function and preserved
EF. A second goal of the present study was to determine whether
Ucn2 gene transfer that was performed in early life (at 3 months
old) could thwart age-related HFpEF in late life. Since many HF
patients are of advanced age, this is particularly relevant, because
treatment of middle-aged patients with early HF might be advan-
tageous in later life. Therefore, in the present study, we test two hy-
potheses: (1) Ucn2 gene transfer will increase LV function in aged
mice, and (2) Ucn2 gene transfer in early life will prevent the devel-
opment of LV dysfunction later in life. In both instances, EF prior
to randomization was >50%.RESULTS
Plasma Ucn2
Plasma Ucn2 was measured 4 months after the delivery of saline or
AAV8.mUcn2 in the treatment study, and 20 months after the deliv-
ery of saline or AAV8.mUcn2 in the prevention study. In addition,
plasma Ucn2 was measured in 7-month-old mice that received saline
at 3 months of age. Plasma Ucn2 levels were similar in the 7-month-
old mice, aged mice that received saline, and in aged mice 20 months
after saline injection (Figure 1).MoTreatment Study
Only male mice were used in the treatment
study (aged female mice were unavailable
from the vendor). Plasma Ucn2 levels were
increased 4 months after delivery (saline:
2.3 ± 0.1 ng/mL, n = 11; Ucn2: 29.1 ± 3.0 ng/
mL, n = 12; p < 0.0001; Figure 1).
Prevention Study
Plasma Ucn2 levels were increased 20 months
after delivery in the prevention study (saline:
2.7 ± 0.1 ng/mL, n = 12; Ucn2: 10.4 ±
1.4 ng/mL, n = 11; p < 0.0001; Figure 1).




Three months after gene transfer or saline treatment, echocardiogra-
phy was performed to assess LV dimensions and EF. Comparing
saline-treated aged mice with saline-treated young mice, the LV pos-
terior wall was thicker (p = 0.0004) and LV strain was higher (p =
0.02) in aged mice. However, EF was not reduced in aged compared
to young mice (Table 1). Compared to saline-treated aged mice, aged
mice that received Ucn2 gene transfer showed higher values for EF
(p < 0.0002) and velocity of circumferential fiber shortening (VCFc;
p < 0.0002) and showed lower LV end-diastolic diameter (EDD;
p = 0.004), LV end-systolic diameter (ESD; p < 0.0002), heart rates
(HRs), and LV strain (p < 0.0002).
Prevention Study
Three-month-old animals were treated with either saline or with
Ucn2 gene transfer (Table 2). When they were compared 20 months
later, Ucn2 gene transfer was associated with higher EF (p = 0.0002)
and VCFc (p = 0.0003) and with lower LV strain (p = 0.002) and ESD
(p = 0.002).lecular Therapy Vol. 28 No 1 January 2020 181
Table 1. Treatment Study, Echocardiography
Young Mice (n = 10)
Aged Mice
+Saline (n = 11) +Ucn2 (n = 12) p Value
HR (bpm) 550 ± 7 545 ± 7 510 ± 8 .008
EDD (mm) 3.9 ± 0.1 4.1 ± 0.1 3.6 ± 0.1 .004
ESD (mm) 2.6 ± 0.1 2.9 ± 0.1 1.9 ± 0.1 <0.0002
IVSd (mm) .8 ± 0.01 .8 ± 0.02 .9 ± 0.03 .7
PWd (mm) .7 ± 0.03 .9 ± 0.03* .8 ± 0.03 .2
EF (%) 64 ± 3 58 ± 3 80 ± 2 <0.0002
VCFc (circ/s) 23 ± 2 21 ± 2 33 ± 2 <0.0002
LV Strain (%) 12.5 ± 0.6 9.7 ± 0.6** 15.3 ± 0.9 <0.0002
Echocardiographic measurements were taken 3 months after saline (Young, +Saline) or
AAV8.mUcn2 (+Ucn2; 1.9  1013 gc/kg) administration. Young mice, 3-month-old sa-
line-injected normal mice; Aged mice, 2-year-old mice; HR, heart rate; bpm, beats per
minute; EDD, LV end-diastolic diameter; ESD, LV end-systolic diameter; IVSd, intra-
ventricular septum thickness at end diastole; PWd, posterior wall thickness at end dias-
tole; EF, ejection fraction; VCFc, velocity of circumferential fiber shortening (corrected
for heart rate); circ, circumference; LV Strain, global longitudinal strain. The p values are
from Student’s t test (unpaired, two-tailed) with Bonferroni correction. Young versus
Aged +Saline: *p = 0.0004; **p = 0.02.
Table 2. Prevention Study, Echocardiography
Saline (n = 20) Ucn2 (n = 16) p Value
HR (bpm) 538 ± 9 537 ± 8 .94
EDD (mm) 3.9 ± 0.1 3.6 ± 0.1 .12
ESD (mm) 2.7 ± 0.1 2.1 ± 0.1 .002
IVSd (mm) .8 ± 0.03 .8 ± 0.03 .38
PWd (mm) .9 ± 0.04 .9 ± 0.05 .73
EF (%) 58 ± 3 72 ± 2 .0002
VCFc (circ/s) 21 ± 1 29 ± 1 .0003
LV Strain (%) 14.8 ± 1.3 20.7 ± 1.2 .002
Echocardiographic measurements were taken 20 months after saline (saline) or
AAV8.mUcn2 (Ucn2, 1.9  1013 gc/kg) administration. HR, heart rate; bpm, beats
per minute; EDD, LV end-diastolic diameter; ESD, LV end-systolic diameter; EF, ejec-
tion fraction; VCFc, velocity of circumferential fiber shortening (corrected for heart
rate); circ, circumference; LV Strain, global longitudinal strain. The p values are from
Student’s t test (unpaired, two-tailed) with Bonferroni correction.
Molecular TherapyLV Function
Treatment Study
Agedmice were treated withUcn2 gene transfer or saline. Youngmice
were treated with saline. Four months later, peak rates of LV pressure
development (LV +dP/dt) were measured using LV pressure cathe-
ters. Compared to young mice, aged mice that had received saline
showed a 37% mean reduction in LV peak +dP/dt (p = 0.0004; Fig-
ure 2A) and a 39% reduction in LV peak dP/dt (p = 0.001) (Fig-
ure 2B). There were also age-related reductions in LV developed
pressure (p < 0.0002; Figure 2C) and heart rate (p = 0.05; Figure 2D).
These data indicate age-related decrements in LV systolic function
and diastolic function. However, EF was preserved (Table 1), an
important component in the definition of clinical HFpEF. Compared
to aged mice that received saline, aged mice that received Ucn2
gene transfer had a 2-fold more rapid LV peak +dP/dt (p < 0.0002;
Figure 2A), a 1.7-fold more rapid LV peak dP/dt (p = 0.004; Fig-
ure 2B), and a higher heart rate (p = 0.0006; Figure 2D).
Prevention Study
Mice that received Ucn2 gene transfer when they were young showed
a 1.7-fold higher LV peak +dP/dt (p = 0.0005; Figure 3A) and a 1.4-
fold higher LV peak dP/dt (p = 0.03; Figure 3B) when studied
20 months after randomization. LV-developed pressure was also
higher in mice that had received Ucn2 gene transfer (p = 0.03; Fig-
ure 3C). No group differences in heart rate were observed.
Necropsy
Treatment Study
Comparing saline-treated aged mice with saline-treated young mice
(Table 3), the body weight and liver:body-weight ratio showed no
group differences. However, there were increases in LV weight (p =
0.03), LV:body-weight ratio (p = 0.04), and lung:body-weight ratio182 Molecular Therapy Vol. 28 No 1 January 2020(p = 0.001) in the older control mice. There were no saline versus
Ucn2 gene transfer group differences in aged mice.
Prevention Study
There were no group differences in body or organ weights 20 months
after saline or AAV8.mUcn2 administration (Table 4).
LV SERCA2a and CaMKII Protein Expression
Treatment Study
LV sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2a) protein
levels were similar in young mice and aged mice that received saline.
However, in aged mice, Ucn2 gene transfer was associated with a 2.9-
fold increase in LV SERCA2a (p = 0.0004; Figure 4A). LV calcium/
calmodulin-dependent protein kinase IIa (CaMKIIa) phosphoryla-
tion was not different between young and aged saline-treated animals.
However, in aged mice, Ucn2 gene transfer was associated with a 46%
lower level of LV p-CaMKII (p = 0.01; Figure 4B).
Prevention Study
In aged mice that had received Ucn2 gene transfer 20 months previ-
ously, LV SERCA2a protein levels were 1.8-fold higher versus those in
mice that received saline (p = 0.01; Figure 4C), and they showed a 39%
reduction of LV p-CaMKII (p = 0.05; Figure 4D).
LV mRNA Expression of Markers of Hypertrophy and Fibrosis
and Duration of Liver Expression
The mRNA expression of several relevant proteins was determined by
RT-PCR.
Treatment Study
Ucn2 gene transfer in aged mice resulted in lower LV mRNA levels of
AT1aR (p = 0.005), B cell lymphoma 2 (Bcl-2; p = 0.008), brain natri-
uretic peptide (BNP; p = 0.04), and a-skeletal actin (p = 0.0008)
(Tables S1 and S2). As expected, mRNA expression of murine Ucn2
was increased (p = 0.0004) in aged mice that received Ucn2 gene
Figure 2. Treatment Study: In Vivo Assessment of LV Function
Young versus aged mice, 4 months after intravenous delivery of AAV8.mUcn2
(1.9 1013 gc/kg) or saline, underwent physiological studies to assess LV function.
(A and B) Peak rate of LV pressure development (A; +dP/dt) and peak rate of LV
pressure decay (B; dP/dt). (C) LV-developed pressure (LVP) was higher in mice
that received Ucn2 gene transfer. (D) Heart rate (HR) in anesthetized animals was
lower in young and aged mice that received saline compared to the aged mice that
received Ucn2 gene transfer. LV, left ventricle; Young, 3-month-old saline-injected
mice; Aged, 2-year-oldmice. Individual data are indicated (mean ±SE). The p values
are fromStudent’s t test (unpaired, two-tailed) with Bonferroni correction for multiple
comparisons; *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant.
Figure 3. Prevention Study: In Vivo Assessment of LV Function 20 Months
after Saline or AAV8.mUcn2 (1.9  1013 gc/kg) Administration
(A and B) Peak rate of LV pressure development (A; +dP/dt) and peak rate of LV
pressure decay (B; dP/dt). These data indicate that AAV8.mUcn2 (Ucn2) gene
transfer increased both peak +dP/dt and peak dP/dt. (C) LV developed pressure
(LVP) was increased by Ucn2 gene transfer. (D) Heart rate (HR) was not altered by
Ucn2 gene transfer. LV, left ventricle. Individual mouse data are shown (mean ± SE
are indicated); p values are from Student’s t test; *p < 0.05; ***p < 0.001; ns, not
significant.
www.moleculartherapy.orgtransfer. Expression levels of four-and-a-half LIM domain protein
1 (FHL-1) were higher in mice that received Ucn2 gene transfer
(p = 0.01).
Prevention Study
LV protein expression was assessed 20 months after saline or
AAV8.mUcn2 administration (Table S3). Mice that received Ucn2
gene transfer had lower mRNA levels of a-skeletal actin (p = 0.05)
and increased levels of FHL-1 (p = 0.008). Murine Ucn2 expression
in the LV was elevated 20 months after gene transfer (p = 0.008).
Liver Ucn2 expression was evaluated 4 months and 20 months after
Ucn2 gene transfer in similarly agedmale mice (Table S4), which indi-
cated a 73% reduction in mRNA levels at 20 months versus 4 months
after gene transfer (p = 0.09). Because we saw sex differences in
plasma levels of Ucn2 (male > female), we examined male versus fe-
male liver Ucn2 mRNA expression in mice in the prevention study,
finding no differences: females: 0.5  106 ± 0.1  106 copies per
microgram of cDNA, n = 6; males: 1.5  106 ± 0.8  106 copies
per microgram of cDNA, n = 5; p = 0.21.
Histological Evaluation of LV and Liver
Treatment Study
Qualitative evaluation of LV and liver tissues showed no differences in
inflammatory infiltrates or fibrosis among the three groups
(Figure S1).Prevention Study
No inflammatory infiltrates or differences in the degree of fibrosis
were found in LV and liver 20 months after saline or AAV8.mUcn2
injection (Figure S2).
DISCUSSION
The twomost important findings in the present study are that urocor-
tin 2 gene transfer (1) increases LV function in aged mice and (2) pre-
vents the development of age-related impairment of LV diastolic
function when delivered to young mice. Preserved EF and impaired
diastolic function, in combination with symptoms of HF, are charac-
teristics of clinical HFpEF, which are seen with increased prevalence
in older patients.1–4
In this study of mice, we could not evaluate symptoms, but we found
age-related impairment of LV diastolic function in the context of EF >
50%, LV hypertrophy, and pulmonary congestion, findings analogous
to what is seen in clinical settings. A recent paper15 highlighted the
complexity of selecting suitable models of clinical HFpEF, and our
model complies with the majority of the suggested requirements.
Our data indicate that Ucn2 gene transfer has beneficial effects in
an animal model that shares features of clinical age-related LV
dysfunction.
It is noteworthy that aging in mice is associated with similar declines
in both LV peak +dP/dt (despite normal EF) and LV peakdP/dt and
that Ucn2 gene transfer provides a remedy for both impairments.
Importantly, aged control mice had higher LV strain than young con-
trol mice, while their EFs were similar (Table 1), which is analogous to
what is seen in clinical age-related HFpEF.16,17 In general, we found,Molecular Therapy Vol. 28 No 1 January 2020 183
Table 3. Treatment Study, Necropsy
Young Mice (n = 10)
Aged Mice
p ValueSaline (n = 11) Ucn2 (n = 12)
BW (g) 31.0 ± 0.5 31.1 ± 0.6 32.8 ± 0.6 .1
LV (mg) 104 ± 4 121 ± 5* 113 ± 5 .6
LV/BW (mg/g) 3.3 ± 0.1 3.9 ± 0.2** 3.5 ± 0.1 .1
Lung/BW
(mg/g)
4.8 ± 0.1 5.9 ± 0.2*** 6 ± 0.3 1
Liver/BW
(mg/g)
45 ± 2 49 ± 2 50 ± 3 1
Necropsy data are from 4 months after saline (Young, +saline) or AAV8.mUcn2
(+Ucn2, 1.9  1013 gc/kg) administration. BW, body weight; LV, left ventricle; young
mice, 3-month-old saline-injected normal mice; aged mice, 2-year-old mice. The p
values are from Student’s t test (unpaired, two-tailed) with Bonferroni correction.
*p = 0.03; **p = 0.04; ***p = 0.001.
Table 4. Prevention Study, Necropsy
Saline (n = 21) Ucn2 (n = 15) p Value
BW (g) 27.8 ± 1 28 ± 1.2 .94
LV (mg) 118 ± 6 115 ± 8 .77
LV/BW (mg/g) 4.3 ± 0.3 4.3 ± 0.4 .9
Lung/BW (mg/g) 6.9 ± 0.4 6.3 ± 0.2 .24
Liver/BW (mg/g) 51.9 ± 2.3 56 ± 3.1 .29
Necropsy data are from 20months after saline or AAV8.mUcn2 (Ucn2, 1.9 1013 gc/kg)
administration. BW, body weight; LV, left ventricle. The p values are from Student’s t
test.
Molecular Therapyin both the treatment and prevention strategies, thatUcn2 gene trans-
fer increased LV diastolic and systolic function, reduced LV dilation,
and reduced LV strain.
We found group differences in direct measures of LV contraction and
relaxation, using micromanometer catheters in the LV cavity. Such
data provide less load-dependent measures of LV function than
does EF. LV peak +dP/dt and peak dP/dt were higher in aged
mice that had received Ucn2 gene transfer 4 months previously, indi-
cating increased LV systolic and diastolic function. Increased heart
rate (HR) can contribute to increased +dP/dt, and we saw an increase
in heart rate in aged mice that received Ucn2 gene transfer (versus sa-
line). However, the force-frequency effect would account for a smaller
change than the 2-fold increase we found.18 Additionally, aged mice
that received Ucn2 gene transfer (versus saline) had lower heart rates
during echocardiography (light anesthesia) but higher heart rates
during deeper anesthesia and mechanical ventilation, which probably
reflects variability in response to anesthetic.
In the prevention study, we asked whether Ucn2 gene transfer per-
formed early in life might prevent age-related abnormalities in LV
function. These studies showed that 20 months afterUcn2 gene trans-
fer (versus saline), age-related LV dysfunction was averted. Indeed,
EF, LV strain, EDD, and ESD were similar whether the mice received
gene transfer when young or as a treatment when old. Finally, we have
shown that a single intravenous delivery of AAV8.mUcn2 results in
sustained high plasma Ucn2 levels 20 months after delivery.
We recently showed that intravenous delivery of AAV8.mUcn2
(2  1013 genome copies [gc]/kg) in male mice provided significant
expression 8 weeks later only in liver (p < 0.0001) and, to a lesser
extent, in left ventricle (p = 0.018).19 In the present study, which
included females, plasma Ucn2 levels were lower in females than in
males, despite having received the same dose of AAV8.mUcn2. We
have seen lower plasma Ucn2 in normal young female versus male
mice after AAV8.mUcn2 injections of the same dose (unpublished
data), suggesting a sex difference in Ucn2 expression or fate. A plau-184 Molecular Therapy Vol. 28 No 1 January 2020sible explanation for this observation is that androgens can signifi-
cantly affect hepatocyte gene transfer.20 In the present study, no sex
differences were found in liver Ucn2mRNA after Ucn2 gene transfer.
The beneficial effects on LV strain and LV dP/dt were somewhat
less in females thanmales, perhaps due to reduced plasma Ucn2 levels
in females. Data analysis included both sexes in the prevention study.
Plasma Ucn2 levels were lower in males that received gene transfer 20
versus 4 months previously, despite having received a similar dose of
AAV8.mUcn2. Liver Ucn2 mRNA was somewhat lower 20 months
versus 4 months after Ucn2 gene transfer (p = 0.09). A decline in
plasma transgene levels was seen also after AAV8-mediated factor
IX gene transfer in macaques, which was attributed to reductions
in liver expression.21 Reduced plasma Ucn2 over time may reflect he-
patocyte turnover, which leads to reduction of the vector DNA over
time, since only one daughter cell will carry the transgene’s
DNA.22,23 Other possibilities, including liver inflammation or necro-
sis, were excluded by the absence of histological abnormalities of
liver (Figure S2). The final plasma Ucn2 level 20 versus 4 months after
delivery is 4-fold basal—which is sufficient to provide beneficial ef-
fects on LV strain, LV peak +dP/dt, and LV peak dP/dt.
We previously reported beneficial effects of Ucn2 gene transfer on
Ca2+ transients in cardiac myocytes isolated from normal young
mice and from young mice with HFrEF.12–14 However, Ca2+ transient
measurements are challenging in aged mice because of poor viability
of isolated cardiac myocytes and, therefore, were not attempted.
Instead, we focused on LV SERCA2a protein expression, a key Ca2+
handling protein, which governs cytosolic Ca2+ handling in sarco-
plasmic reticulum. Previous papers suggest that Ucn2 peptide treat-
ment has beneficial effects on cardiac myocyte Ca2+ handling,24
which increases Ca2+ concentrations at the myofilaments during
contraction, and consequently increases the force of contraction.
We found that LV SERCA2a levels were similar in young and aged
mice that received saline. However, in the treatment study, Ucn2
gene transfer was associated, 4 months later, with a 2.9-fold increase
in LV SERCA2a. Increased expression of SERCA2a would be ex-
pected to increase cytosolic Ca2+ decline, resulting in improved relax-
ation, and would also contribute to increased systolic function. We
previously have shown by telemetry in unsedated untethered mice
that mean daily heart rate and basal systolic and diastolic blood
Figure 4. Levels of LV Proteins after Intravenous Delivery of AAV8.mUcn2
(1.9  1013 gc/kg) or Saline
(A) LV sarco/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) levels were
increased in aged mice that received Ucn2 gene transfer (p = 0.0004 versus saline).
(B) LV p-CaMKIIa was reduced in AAV8.mUcn2-treated aged animals (p = 0.01
versus saline). (C and D) LV SERCA2a levels were increased (C) and LV p-CaMKIIa
was reduced (D) 20 months after Ucn2 gene transfer. Data are normalized to
GAPDH. Representative immunoblots for the summary data are shown below the
graphs. Individual data are indicated (mean ± SE). Young, 3-month-old saline-in-
jected mice; Aged, 2-year-old mice. The p values are from Student’s t test (un-
paired, two-tailed) with Bonferroni correction for multiple comparisons; *p < 0.05;
**p < 0.01; ***p < 0.001.
www.moleculartherapy.orgpressure are unaffected by Ucn2 gene transfer,14 underscoring the
importance of direct cardiac effects on Ca2+ handling as the mecha-
nism for the beneficial effects of Ucn2 gene transfer on LV diastolic
function.
There was no difference between young and aged saline-treated ani-
mals in the phosphorylation levels of CaMKIIa in LV samples. How-
ever, Ucn2 gene transfer in aged mice was associated with lower LV
levels of p-CaMKIIa, an alteration that can benefit cardiac perfor-
mance.25 Increased levels of LV p-CaMKIIa are associated with pro-
gressive LV dysfunction, by affecting hypertrophic and inflammatory
gene expression, and with arrhythmias.25 In the prevention study,
20 months after Ucn2 gene transfer, we saw a 1.9-fold increase in
LV SERCA2a and reduced p-CaMKIIa levels. Further studies will
be required to elucidate the molecular mechanisms underlying in-
creases in LV SERCA2a and reduced p-CaMKII.
In the treatment study, mRNA expression of proteins related to car-
diac hypertrophy and stress showed that LV b2AR expression was
increased in agedmice versus youngmice. However,Ucn2 gene trans-
fer in agedmice was associated with reductions inAT1aR, Bcl-2, BNP,
and a-skeletal actin and increases in FHL-1 and Ucn2. Reductions in
BNP, Bcl-2, and a-skeletal actin may reflect reduced stress after Ucn2
gene transfer, due to improved LV function.26–29 SERCA2a mRNAwas unchanged, despite a 2.9-fold elevation in LV SERCA2a protein
after Ucn2 gene transfer—this implies a change in mRNA stability or
reduction in SERCA2a protein turnover after Ucn2 gene transfer. In
the prevention study, LV expression of b1 adrenergic receptor, b2AR,
and a-skeletal actin was reduced, indicating reduction of cardiac
stress, and expression of FHL-1 and murine Ucn2 were increased.
We assessed LV fibrosis usingMasson’s trichrome, as well as Picrosir-
ius red staining. We did not find age-related increases in the LV
collagen deposits. A similar absence of increased LV fibrosis has
been reported by others.30–32
We are not proposing that Ucn2 gene transfer be used to prevent the
future occurrence of age-related LV dysfunction. However, the two
strategies (prevention and treatment) had similar results on multiple
measures of LV structure and function and of biochemical alterations
in the heart, which serves to embolden the conclusion that Ucn2
gene transfer affects LV function through beneficial effects on LV
SERCA2a and CaMKII. In addition, the absence of deleterious effects
on LV structure and function or adverse histological effects, despite
nearly 20 months of sustained increased concentrations of plasma
Ucn2, indicates not only that the benefits of Ucn2 gene transfer are
prolonged after a single injection but also that sustained increases
in plasma Ucn2 are safe.
There are two previous reports of gene transfer treatments for animal
models of LV diastolic dysfunction. In aged rats, thoracotomy-based
delivery of adenovirus encoding parvalbumin, which may benefit
myocardial Ca2+ handling, was reported to have a beneficial effect
on LV relaxation in anesthetized animals studied 2 days after gene
transfer.33 No subsequent studies were reported. A more recent study
examined streptozotocin-treated diabetic mice with diastolic abnor-
malities detected by echocardiographic analysis of LV filling. Further
abnormalities were attenuated 6–8 weeks later by phosphoinositide
3-kinase gene transfer via intravenous delivery of an AAV6 vector.34
Our present study shows not only prevention of age-related LV dia-
stolic abnormalities 20 months after delivery but also, as shown in the
treatment arm, full restoration of normal LV function. Furthermore,
the approach that we used—gene transfer of a peptide with paracrine
actions that benefit cardiac function—is a novel approach that does
not require high transgene expression levels in the heart and can be
delivered by an intravenous injection.
There are inherent shortcomings in translating studies in mice to
clinical applications, and our findings must be confirmed in larger
animal models of HFpEF. Some will criticize our failure to use stan-
dard echocardiographic measures of diastolic function in the present
studies. However, we used two assessments of diastolic function that
are not hampered by the rapid heart rates in mice: LV peak dP/dt,
the peak rate of LV pressure decay during diastole, and LV strain.
These two measures provide sensitive and accurate assessments
of LV diastolic function that are superior to the usual echocardio-
graphic measurements.16 Indeed, LV strain has been recently sug-
gested as a standard for the evaluation of diastolic function in clinical
HFpEF.17 Additional insights from our data include a sex differenceMolecular Therapy Vol. 28 No 1 January 2020 185
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underscoring the desirability of including both sexes in preclinical
and clinical studies, and the slow decline in AAV8-mediated liver
expression over time, likely due to normal hepatocyte turnover.
Fortunately, we used a dose of vector sufficiently high to enable a
>4-fold elevation in plasma Ucn2 20 months after delivery.
In conclusion, Ucn2 gene transfer improves both systolic function
and diastolic function in mice with age-related LV dysfunction and
prevents development of LV dysfunction when given to young
mice. The mechanism for these beneficial effects lies, at least in
part, in increased LV SERCA2a expression. These findings are poten-
tially relevant for treatment of clinical age-related LV dysfunction.
The therapy may be particularly effective for clinical HFpEF, a disease
that, to date, has few effective therapies.
MATERIALS AND METHODS
AAV8.mUcn2 Vector
HEK293T cells were transfected with the pRep2/Cap8 and pAd-Help-
er plasmids,14 for the production of an AAV8 vector encoding murine
Ucn2 driven by a chicken b-actin (CBA) promoter (AAV8.CBA.
mUcn2; Figure 1A). Plasmid pRep2/Cap8 was obtained from the Uni-
versity of Pennsylvania Vector Core. Virus vectors were then purified
and concentrated as previously described.13,35 Real-time PCR with vi-
rus genome DNA prepared from purified virus was used to quantify
virus titers.
Animal Use
The Animal Use and Care Committee of the Veterans Affairs San
Diego Healthcare System approved the studies. In this study, to
answer our first hypothesis, we used 10male mice (C57BL/6J; Jackson
Laboratories, Bar Harbor, ME, USA) 10.7 ± 0.6 weeks old (treatment
group, young), weighing 27.8 ± 0.5 g, and 23 male mice (C57BL/6J)
102 weeks old (treatment group, aged), weighing 33.4 ± 0.5 g (Fig-
ure 1Bi). To address our second hypothesis, we used 29 male mice
(C57BL/6J) 11.9 ± 0.4 weeks old, weighing 26.4 ± 0.5 g, and 19 female
mice (C57BL/6J) 10.2 ± 0.1 weeks old (prevention group), weighing
18.5 ± 0.2 g (Figure 1Bii). From those 48 mice in the prevention
group, 5 that received saline and 6 that received AAV8.mUcn2 died
before the terminal study. All of the mice were provided (ad libitum)
a cereal-based diet (Harlan Teklad Laboratory, Madison, WI, USA)
and tap water. Mice were housed (20C–21C) with lights off from
6 p.m. to 6 a.m. daily.
Ucn2 Gene Transfer
Under anesthesia (1.5% isoflurane via nose cone), the jugular vein was
exposed. AAV8.mUcn2 (1.9  1013 gc/kg in 100 mL) or a similar vol-
ume of saline was delivered using a syringe with a 31G needle.
Echocardiography
Echocardiography was performed as previously described,12 using
a Vevo 3100 ultrasound system with an MX550s transducer and
VevoLab v3.1 analysis software (VisualSonics, Toronto, ON, Can-
ada), to document LV function and to record LV chamber dimen-186 Molecular Therapy Vol. 28 No 1 January 2020sions. LV strain was calculated by VevoLab v3.1 analysis software,
from planimetered LV wall changes during diastole and systole on
a long-axis view.
LV Function
Using a 1.4-F micromanometer catheter (SPR 839, Millar Instru-
ments, Houston, TX, USA), the LV pressure signal was recorded,
stored digitally, and then processed (IOX v2.9.5, Emka Technologies,
Christchurch, VA, USA) as previously reported.36 The first
derivatives of LV pressure development (LV +dP/dt) and decline
(LV dP/dt) were used to define LV systolic function and diastolic
function, respectively.
Plasma Ucn2
In the terminal study under anesthesia, the carotid artery was bled,
and blood was collected (with EDTA) and centrifuged (1,600  g,
15 min). Plasma was collected and stored at 80C. Plasma Ucn2
levels were measured using a mouse urocortin 2 enzyme immuno-
assay (EIA) kit (Kamiya Biomedical, Seattle, WA, USA).
RT-PCR, PCR, and Immunoblotting
LV and liver samples were collected and stored at80C. Total RNA
was isolated and reverse transcribed into cDNA that was used in
qPCR as previously described.12 Additionally, Ucn2 gene mRNA
was reverse transcribed into cDNA that was amplified and quantified
(copies per microgram of cDNA) using an ABI TaqMan 7700 System
(Applied Biosystems, Foster City, CA, USA) according to the manu-
facturer’s instructions. All gene-specific primers used in PCR are
listed in Table S1. Immunoblotting was performed as described pre-
viously.12 The following antibodies were used: phospho-CaMKII
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and SERCA2a
(Enzo Life Sciences, Farmingdale, NY, USA).
Necropsy and Histology
Body, liver, lung, and LV weight (including interventricular septum)
were recorded. Samples of liver and transmural LV were formalin
fixed and paraffin embedded. Five-micron sections were mounted
and counterstained with H&E and with Masson’s trichrome. Slides
were then scanned using an Axio Scan.Z1 slide scanner (Zeiss, Ober-
kochen, Germany) and analyzed with ImageJ v1.49 software (Be-
thesda, MD, USA).
Statistical Analysis
Data acquisition and analysis were done without knowledge of group
identity. Group sizes were determined by power calculations. We
used only male mice, because aged female mice were not available
from the vendor. The hypothesis was that Ucn2 gene transfer would
effectively treat LV diastolic dysfunction in aged mice. First, young
versus aged mice that received intravenous saline were compared to
establish that LV diastolic dysfunction was present in aged mice. Sub-
sequently, aged mice that received Ucn2 gene transfer versus saline
were compared to determine whether Ucn2 gene transfer in aged
mice was associated with increased LV diastolic function. To test
for group differences, Student’s t test (unpaired, two-tailed) was
www.moleculartherapy.orgused. Bonferroni correction was used for multiple testing. Analyses
were performed using GraphPad Prism v6.07 (GraphPad Software,
San Diego, CA, USA). The null hypothesis was rejected when p < 0.05.
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